Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.12 +2.5%	$2.81	$1.05 ▼ $3.98	$301.50M	1.89	597,465 shs	355,949 shs
GOSS Gossamer Bio	$1.71 +3.0%	$1.26	$0.66 ▼ $1.80	$377.32M	1.86	1.46 million shs	6.19 million shs
INCR InterCure	$1.50	$1.52	$1.17 ▼ $2.62	$68.36M	1.18	25,911 shs	17,482 shs
OCGN Ocugen	$1.00 -3.8%	$0.96	$0.52 ▼ $1.80	$303.71M	4.18	4.55 million shs	4.31 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+1.63%	-5.46%	-4.59%	+156.38%	-17.37%
GOSS Gossamer Bio	+3.01%	+25.74%	+37.90%	+103.57%	+56.88%
INCR InterCure	0.00%	-7.41%	-0.07%	+9.09%	-37.76%
OCGN Ocugen	-3.85%	-13.04%	-8.26%	+47.19%	-45.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.5729 of 5 stars	3.5	1.0	0.0	1.3	0.8	0.6
GOSS Gossamer Bio	3.7985 of 5 stars	3.5	1.0	4.7	2.6	1.7	0.0
INCR InterCure	0.5684 of 5 stars	0.0	3.0	0.0	2.8	0.0	0.6
OCGN Ocugen	1.1705 of 5 stars	3.5	1.0	0.0	1.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	148.80% Upside
GOSS Gossamer Bio	3.00	Buy	$8.25	382.46% Upside
INCR InterCure	0.00	N/A	N/A	N/A
OCGN Ocugen	3.00	Buy	$6.00	500.00% Upside

Current Analyst Ratings Breakdown

Latest INCR, ADCT, GOSS, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
6/24/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/24/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/12/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
5/12/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	4.36	N/A	N/A	($2.10) per share	-1.48
GOSS Gossamer Bio	$114.70M	3.39	N/A	N/A	$0.13 per share	13.15
INCR InterCure	$64.55M	N/A	N/A	N/A	$2.36 per share	N/A
OCGN Ocugen	$4.05M	72.11	N/A	N/A	$0.10 per share	10.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.45	N/A	N/A	N/A	-197.64%	N/A	-45.57%	8/5/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
INCR InterCure	-$18.32M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)
OCGN Ocugen	-$54.05M	-$0.19	N/A	N/A	N/A	-1,271.12%	-223.00%	-92.20%	8/14/2025 (Estimated)

Latest INCR, ADCT, GOSS, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	OCGN Ocugen	-$0.06	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
8/5/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	N/A	N/A	N/A	$17.82 million	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/9/2025	Q1 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	N/A	$1.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.46	4.16
GOSS Gossamer Bio	6.70	5.71	5.71
INCR InterCure	0.34	1.73	1.18
OCGN Ocugen	1.74	2.60	2.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
GOSS Gossamer Bio	81.23%
INCR InterCure	8.34%
OCGN Ocugen	10.27%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
GOSS Gossamer Bio	6.70%
INCR InterCure	0.24%
OCGN Ocugen	4.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	93.82 million	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
INCR InterCure	350	N/A	N/A	Optionable
OCGN Ocugen	80	292.03 million	279.12 million	Optionable

INCR, ADCT, GOSS, and OCGN Headlines

Recent News About These Companies

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

July 17 at 6:30 AM | globenewswire.com

Ocugen (NASDAQ:OCGN) Shares Down 2.8% - Should You Sell?

July 17 at 3:04 AM | marketbeat.com

Ocugen's (OCGN) "Buy" Rating Reaffirmed at HC Wainwright

June 24, 2025 | marketbeat.com

Ocugen (NASDAQ:OCGN) Given "Buy" Rating at Chardan Capital

June 24, 2025 | marketbeat.com

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

June 23, 2025 | globenewswire.com

Ocugen: Three Potential Gene-Therapy Filings By 2028

June 18, 2025 | seekingalpha.com

Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease

June 17, 2025 | msn.com

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate ...

June 16, 2025 | gurufocus.com

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

June 16, 2025 | globenewswire.com

Ocugen, Inc. to Present at 2025 BIO International Convention, Showcasing Gene Therapy Advancements for Blindness Diseases

June 11, 2025 | quiverquant.comQ

Ocugen To Present at BIO International Convention 2025

June 11, 2025 | globenewswire.com

Ocugen signs binding term sheet for license of OCU400 modifier gene therapy for retinitis pigmentosa in Korea

June 7, 2025 | pharmabiz.comP

Ocugen Secures Licensing Agreement for OCU400 in Korea

June 6, 2025 | msn.com

Ocugen signs term sheet for korean licensing of OCU400 gene therapy

June 5, 2025 | ophthalmologytimes.comO

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

June 5, 2025 | globenewswire.com

Ocugen’s OCU410ST receives Rare Pediatric Disease Designation for the treatment of ABCA4-associated retinopathies

May 27, 2025 | ophthalmologytimes.comO

Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment

May 27, 2025 | msn.com

Ocugen, Inc. Receives FDA Rare Pediatric Disease Designation for OCU410ST in Treatment of ABCA4-Associated Retinopathies

May 27, 2025 | quiverquant.comQ

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025 | globenewswire.com

The Analyst Verdict: Ocugen In The Eyes Of 5 Experts

May 14, 2025 | nasdaq.com

Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy

May 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Marvell's New AI Chip Deals Capture Wall Street’s Attention
By Jeffrey Neal Johnson | June 21, 2025
View Marvell's New AI Chip Deals Capture Wall Street’s Attention
Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow
By Thomas Hughes | June 18, 2025
View Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow
Best Prime Day Ever? Here Are the Prime Winners Riding the Wave
By Thomas Hughes | July 14, 2025
View Best Prime Day Ever? Here Are the Prime Winners Riding the Wave
Qualcomm: A Technical Setup Is Emerging, and It's Bullish
By Sam Quirke | June 18, 2025
View Qualcomm: A Technical Setup Is Emerging, and It's Bullish

INCR, ADCT, GOSS, and OCGN Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.12 +0.08 (+2.47%)

Closing price 07/17/2025 03:59 PM Eastern

Extended Trading

$3.21 +0.09 (+3.05%)

As of 05:43 AM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Gossamer Bio NASDAQ:GOSS

$1.71 +0.05 (+3.01%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$1.78 +0.06 (+3.80%)

As of 05:59 AM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

InterCure NASDAQ:INCR

$1.50 0.00 (0.00%)

Closing price 07/17/2025 03:48 PM Eastern

Extended Trading

$1.49 -0.01 (-0.60%)

As of 07/17/2025 05:12 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Ocugen NASDAQ:OCGN

$1.00 -0.04 (-3.85%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$1.01 +0.01 (+1.10%)

As of 06:22 AM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time